MedTrace Logo

Disulfiram and Cisplatin in Refractory TGCTs.

NCT03950830 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-10-04

No results posted yet for this study

Summary

Non-randomized, open-label, single center trial to assess efficacy (as measured by overall response rate (ORR) by RECIST 1.1 of disulfiram and cisplatin in patients with multiple relapsed/refractory germ cell tumors (GCTs).

Conditions

  • Germ Cell Tumor

Interventions

DRUG

Disulfiram

Disulfiram 400mg daily, continuously

Sponsors & Collaborators

  • National Cancer Institute, Slovakia

    lead OTHER_GOV

Principal Investigators

  • Michal Mego, Prof · National Cancer Institute, Slovakia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-14
Primary Completion
2021-09-30
Completion
2022-01-31

Countries

  • Slovakia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03950830 on ClinicalTrials.gov